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Abstract (212 words) 
BACKGROUND: Patients with attention-deficit/hyperactivity disorder (ADHD) are more 
prone to physical injuries, including motor vehicle accidents, fractures and brain injuries 
Several observational studies have been published investigating the association between the 
use of pharmacological treatment for ADHD and the incidence of physical injuries among 
patients with ADHD; however, the findings are not concordant.  
OBJECTIVE: This study is a systematic review and meta-analysis of the existing literature 
and estimates the overall association between the use of ADHD medications and physical 
injury. Injury is defined as medically attended physical injuries in the form of hospitalisations, 
emergency department visits or general practitioners visits. 
METHODS: PubMed, EMBASE, PsycINFO, CINAHL and the Cochrane Review databases 
were searched for relevant studies published up to May 2017 related to ADHD medication 
and risk of injuries. Observational study with any study design, all age group (children and 
adults) and all ADHD medications (stimulant and non-stimulants) were included. Studies 
relevant to the association between ADHD medication exposure and risk of injuries in ADHD 
patients were extracted and compiled for meta-analysis. Both within-individual and between-
individual analysis were conducted.  
RESULTS: 2001 citations were identified and ten observational studies were included. Three 
self-controlled case series and two self-controlled cohorts were eligible for meta-analysis of 
within-individual studies. Five cohort studies were included in meta-analysis of between-
individual studies. The adjusted rate ratio of the within-individual methods was 0.76 (95%CI 
0.61 to 0.93) and 0.88; 95% CI, 0.85-0.92 for between-individual studies.  
CONCLUSION: The findings of this meta-analysis support a reduced risk of injuries among 
ADHD patients who were treated with ADHD medications. 
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 Patients with ADHD are prone to sustaining injuries that require medical attention. 
 Pharmacological treatment can reduce ADHD symptoms and may reduce injury risk. 
 Use of medication was associated with lower rates of medically attended physical 
injuries in the form of hospitalisations, emergency department visits or visits to general 
practitioners. 
 Similar protective association was found in both genders.  





Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder 
characterised by hyperactivity, impulsivity, and cognitive dysfunction [1, 2]. ADHD often 
causes major negative impact in one’s daily life and generally patients with ADHD are more 
prone to injuries including motor vehicle accidents, fractures and brain injuries [3]. Risk of 
injury to children and adolescents with ADHD might be mediated by several factors, such as 
impairment of motor functions, developmental coordination disorders or other core symptoms 
[4]. Indeed, core ADHD symptoms such as impulsivity, inhibitory deficits as well as 
inattention to surroundings may be the major factors to accidents. Pharmacological treatments 
such as methylphenidate, dexamphetamine, or atomoxetine are effective in the treatment for 
ADHD symptoms [1]. Stimulant medication use was hypothesised to decrease injury risk by 
reducing ADHD symptoms such as inattention or impulsivity [5, 6]. Indeed, a large number 
of the studies based on artificial laboratory simulations have shown that ADHD treatment 
reduces “errors and accidents” [7]. Some published studies have reported the association 
between ADHD medications and lower risk of injuries in ADHD [5, 6] while other did not 
report the same findings [8, 9]. The impact of ADHD medications in the prevention of 
physical injury still remains uncertain. In view of the above issues, we undertook a systematic 
review and meta-analysis of published studies to evaluate the effectiveness of ADHD 
medications in reducing injuries in the real-life setting. 
 
2. Method 
A systematic literature search was conducted using the search terms listed in 
Appendix A. PubMed, EMBASE, PsycINFO, CINAHL and the Cochrane Review databases 
were searched up to 15th May 2017. Only English studies were included. Titles and abstracts 
were screened and full texts of relevant articles were retrieved for further review to identify 
relevant studies. This study was conducted in accordance with the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses (PRISMA) for guidelines to ensure clear and 
comprehensive reporting.  
  
2.1 Inclusion and exclusion criteria 
Inclusion: 
A. Analytical observational studies using cohort, case control, self-controlled case series or 
case crossover study design. 
B. Studies must report the association between ADHD medication use, stimulants 
and/or non-stimulants, and the risk of injuries. Injuries is defined as “medically attended 
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physical injuries in the form of hospitalisations, emergency department (ED) visits or general 
practitioner (GP).visits” 
C. Studies on children, adolescents and/or adults.  
Exclusion criteria: 
A. Case reports  
B. Animal studies. 
  
2.2 Quality assessment 
As recommended by the Cochrane Collaboration [10], the included studies were 
assessed for methodological quality using the Newcastle-Ottawa scale (NOS) [11]. Three 
authors (ML, EM and SL) independently reviewed and scored each study. Disagreements 
were resolved through discussions. A maximum of nine stars could be allocated for the 
following categories: selection, comparability and outcome. The total score was obtained by 
adding the number of stars in the sub-categories where a higher score indicated better quality. 
 
2.3 Data extraction 
Data from the included studies were extracted using a standardised data collection 
form. These included study duration and design, data source, outcome definition and effect 
size. Authors ML, EM, SL and WQ independently extracted data and completed the 
characteristics form that was subsequently cross-matched to ensure consistency and accuracy. 
Information for each study was extracted by two authors. Outcome parameters such as the 
adjusted incidence rate ratio (IRR), hazard ratio (HR), odd ratio (OR), rate ratio (RR) and the 
corresponding 95% confidence intervals (CI) were extracted and included in the meta-
analysis if appropriate. Studies where such statistics could not be included in the meta-
analysis were summarised in the narrative review. The primary outcome of interest was the 
risk of injuries following exposure to ADHD medications among patients with ADHD 
relative to patients or patient-time without medications. Any data on physical injuries such as 
open wounds, fractures, transport accidents and falls recorded from all points of care such as 
GP visits, hospitalisation and ED admissions were extracted for inclusion.  
 
2.4 Statistical analysis 
To estimate the association between the use of ADHD medications and incidence of 
injuries, the results of the included studies were combined using DerSimonian and Laird’s 
random-effects model [12] to account for heterogeneity among studies. Analysis was 
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performed on the adjusted estimates from the studies. The pooled estimates with 95% CI were 
calculated.   
As the studies included in the analysis were conducted in different settings, we 
examined the extent of heterogeneity among studies with the Cochran Q test [12], where a 
cut-off p-value of 0.1 was considered significant for heterogeneity. Higgin’s I2-statistic was 
reported for each figure to indicate the degree of heterogeneity [12]. All analyses were 
conducted using Review Manager 5.3 (Copenhagen: The Nordic Cochrane Centre, The 
Cochrane Collaboration, 2014). 
3. Results 
PubMed, EMBASE, PsycINFO, CINAHL and Cochrane review database were 
searched, up to May 2017, with 1343, 444, 92, 122, 0 records identified from each database 
respectively, yielding 2001 records in total and 1322 records after removing duplicates 
(Figure 1). Titles and abstracts were screened and full texts were retrieved for further 
assessment of 26 relevant records, of which 10 studies were found to be relevant. Six of the 
studies [6, 13-17] were  conducted using nationwide databases, with two [15, 16] from the 
same nationwide claim database in Taiwan, three others [4, 18, 19] from insurance claim 
databases and one [5] from GP database, all with substantial numbers of patients. All studies 
evaluated physical injuries as the outcome, which was defined as medically attended injuries 
at any point of care, identified diagnoses for injury on database records, or through entries for 
trauma or transport-related injuries on medical records. Two studies [4, 13] limited the 
outcome to hospitalisations and three cohort studies [6, 14, 19] limited to ED visits from 
trauma- or transport-related injuries; while the remaining five incuded studies [5, 15-18] 
included attended injuries at all recorded points of care. All studies reported methylphenidate 
as a medication used in ADHD patients. ADHD medications studied were limited to 
methylphenidate only in two of the studies [6, 15], while one study [5] included stimulant 
medications only and the remaining seven studies [4, 13, 14, 16-19] included stimulant and 
non-stimulant medications. The characteristics and summary of results of the included studies 
are shown in Table 1, Figure 2a and 2b. The quality assessment of the included studies is 
shown in Table 2. Four cohort studies [13, 15, 16, 18] had six to seven out of nine stars from 
the NOS scale which are with adequate quality. As all cohort studies compared treated 
individuals to untreated individuals, they lost two stars from the “comparability” criteria. 
Other six studies [4-6, 14, 17, 19] had the full nine stars which were considered at high 
quality. Six out of the ten included studies [5, 6, 14, 16, 17, 19] reported significant 
association between injuries and ADHD medications use with a lower risk/incidence of injury 
in treated patients or treated periods. While the remaining four studies [4, 13, 15, 18] did not 
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find a significant association, the results were favourable towards the use of medications 
being associated with lower risk of injuries.  
Three of the studies [4-6] were self-controlled case series studies, reporting within-
individual comparisons only [20]. The remaining seven studies [13-19] were cohort studies, 
one [17] with within-individual analysis only, four [13, 15, 16, 18] with between-individual 
analyses only and two [14, 19] with both between-individual and within-individual analyses. 
The within-individual analyses and between-individual analyses were included in separate 
meta-analyses. In each of the meta-analyses, the results were separated into subgroups of 
children and adults, as the safety and effectiveness of ADHD medications were less well 
studed in adults. The stratification of children and adults was according to definitions by 
investigators, with children defined as aged 18-21 or lower [4-6, 13, 15, 17] and adults 
defined as aged 18 or older [14, 16, 18, 19].  
 
3.1 Meta-analysis of within-individual analyses 
Three self-controlled case series (SCCS) and within-individual analysis of three 
cohort studies were included in the meta-analysis, comprising a total of 253,612 cases from 
databases in the United States, Sweden, Hong Kong, Germany, Denmark and the United 
Kingdom respectively [4-6, 14, 17, 19]. The study periods ranged from 1990 to 2014, with 
individual study spanning between 4 and 15 years (Table 1). The relative risk of injuries was 
significantly lower in the medicated periods (pooled RR=0.76; 95% CI, 0.61-0.93) (Figure 3). 
No significant difference was observed between different within-individual study designs 
(subgroup Q-statistics = 2.52, p=0.11, I2 = 60.3%) (Figure 3). Lower risk of injuries was 
found (subgroup Q-statistics = 50.70, p < 0.01, I2 = 98.0%) in the medicated periods in adults 
(pooled RR, 0.60; 95% CI, 0.57-0.63) than in children (pooled RR, 0.86; 95% CI, 0.79-0.93). 
A high heterogeneity was found across the studies (Q-statistics = 126.42, p <0.01, I2 = 96%) 
(Figure 4). The heterogeneity may be the result of the difference in the outcome measures, the 
statistical analysis used and the ADHD medications included across the six studies. 
  
3.2 Meta-analysis of between-individual analyses 
The between-individual results from six cohort studies [13-16, 18, 19] were included 
in the meta-analysis, comprising 2,347,656 ADHD patients across the cohorts, among which 
1,964,855 patients received medications. Two studies were from databases in the United 
States [18, 19], two from Taiwan [15, 16], and one each from Sweden [14] and Netherlands 
[13]. As Chien et al. [16] used the same database as Chen et al. [15], Chien et al’s study [16] 
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was not included in the main meta-analysis for between-individual analyses to avoid double-
up of results; however it was substituted for Chen et al. [15] in the sensitivity analysis to 
assess the impact on the overall results. The study periods ranged from 1996 to 2014, with 
individual studies spanning over 4 to 17 years (Table 1). The risk of injuries was significantly 
lower in the medicated individuals (pooled RR, 0.88; 95% CI, 0.85-0.92). A low 
heterogeneity was found between the studies (Q-statistics = 3.96, p = 0.41, I2 = 0%) (Figure 
5). Sensitivity analysis by subsituting Chen et al. with Chien et al. showed similar results 
(pooled RR, 0.86; 95% CI, 0.80-0.92). Similarly, low heterogeneity was observed (Q-
statistics = 4.65, p = 0.33, I2 = 14%) (Figure 6).  
In the subgroup analysis, the risk of injuries were found to be significantly lower in 
the adults only (pooled RR, 0.86; 95% CI, 0.78-0.94) while no significant association was 
found in children (pooled RR, 0.93; 95% CI, 0.83-1.03) (Figure 7). However, no significant 
difference was found between the pooled estimates in children and adults (Q-statistics = 1.16, 
p = 0.28, I2 = 13.9%). 
  
4. Discussion 
The results of all identified observational studies were largely favourable towards the 
use of medications being associated with reduction injuries as defined as “medically attended 
physical injuries in the form of hospitalisations, emergency department visits or general 
practitioners visits”. Four out of the seven cohort studies [14, 16, 17, 19] and two out of three 
self-controlled case series studies [5, 6] showed significant association between injuries and 
ADHD medications use. While the remaining three cohort studies [13, 15, 18] and one self-
controlled case series study [4] were unable to show the significant association, the 
nonsignificant finding may be due to insufficient statistical power. 
When the within-individual analysis results of three cohort studies [14, 17, 19] and 
three self-controlled case series studies [4-6] were pooled in the meta-analysis, reduction in 
injuries in patients was shown with the incidence significantly lowered by 24% (95% CI 7%-
39%) during medication use as opposed to non-medicated periods, although a high 
heterogeneity was observed among the studies. The different statistics used in reporting the 
risk of injuries, including OR [17, 19], IRR [4-6] and HR [14], may contributed to the 
heterogeneity. The different outcome measures, with studies including injury treated at all 
points of care [5, 17], hospitalisations only [4] and ED visits only [6, 19] respectively, may 
have also contributed to the heterogeneity. The variation in the ADHD medications in the 
studies ranging from methylphenidate only [6] to both stimulant and non-stimulant 
medications included [4, 17, 19] could be another source of heterogeneity. While significant 
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lower risk of injuries was found in both children and adults in the subgroup analysis, a greater 
effect was found in adults (40%, 95% CI 37%-43%) compared with children (14%, 95% CI 
7%-21%) (Q-statistics = 50.70, p < 0. 01). The heterogeneity found in the subgroup analysis 
for children (Q-statistics = 5.84, p = 0.12, I2 = 49%) and adults (Q-statistics = 0.05, p = 0.83, 
I2 = 0%) were low to moderate. The difference in effect in children and adults could be a 
contributor to the heterogeneity found in the overall meta-analysis of all within-individual 
analyses. Given such high heterogeneity, the results need to be interpreted cautiously. 
When the between-individual results of the five cohort studies [13-15, 18, 19] were 
pooled in the meta-analysis, risks of injuries in ADHD patients was also shown to be 
significantly lowered by 12% (95% CI 8%-15%) when medicated as compared to not 
medicated. Low heterogeneity was found across the studies (Q-statistics = 3.57, p = 0.47, I2 = 
0%). In the subgroup analysis, significant association was not found in children (pooled RR, 
0.93; 95% CI, 0.84-1.10) while a 12% lower risk (pooled RR=0.86, 95% CI 0.78-0.94) was 
found in adults. However, the test for subgroup difference did not show significant difference 
in study results between children and adults (Q-statistics = 1.16, p = 0.28, I2 = 13.9%). The 
nonsignificant result in children may be due to the insufficient power of the study design.  
In two of the studies [5, 14], a lower risk was only found in treated males but not 
females. This may be due to the number of female cases identified being 33% to 85% fewer 
than that of male, resulting in insufficient statistical power to show significant finding. 
Age-stratified analysis in two of the studies [6, 17] found that the benefit of injury 
reduction was greater in older adolescents, which is consistent with our finding from 
subgroup meta-analysis that the benefit of ADHD medications on injury reduction may be 
associated with age, with  greater beneficial effect found in adults than in children.  
 Currently, injury prevention is not the indication of ADHD medications.. In this 
study, we found that the use of ADHD medication was associated with a significant lower 
risk of injury. This protective effect was clearly present not only in children and adolescents 
but also in adults which highlighted the importance of the medication on the well-being of 
ADHD patients. However, pharmacological treatment is part of the comprehensive treatment 
programme for ADHD, which incorporates psychosocial interventions as well. The initiation 
of drug treatment should accompany with careful clinical evaluation including an accurate 
diagnosis, clear impairment in function due to ADHD, and weighting the risks and benefits of 
the medication. 
Randomised clinical trial (RCT) is recognised as the gold standard to evaluate  
efficacy of pharmacological interventions. However, it is also recognised that RCT is not an 
effective method to evaluate real-life outcomes due to relatively short duration of trial and 
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relatively small sample size. On the other hand observational studies are more appropriate to 
evaluate outcomes in real-life practice. The major strength of observational studies using 
clinical/adminstrative databases is the large sample size and long follow-up time. These 
provided a valuable basis to investigate the association of  between ADHD treatment and 
some rare adverse outcomes such suicidal attempts, psychosis and mortality [21-23]. This 
meta-analysis identified ten large observational studies using clinical or administrative 
databases because these databases can provide information on injury-related medical 
encounter with large sample size and long-term follow-up . However, observational study is 
also prone to bias if confounding effects are not properly addressed. We conducted quality 
assessment on the included studies and all of them are with good quality. Six included studies 
[4-6, 14, 17, 19] with full stars in NOS scale applied within-individual study design. This 
could effectively remove time-invariant confounding effects to obtain an accurate estimate. 
On the other hand, the results from the four cohort studies (between-individual design) [13, 
15, 16, 18] are similar to the pooled estimates of the within-individual design which showed 
robustness of the results. In addition, the evidence from observational studies reflected the 
real-world effectiveness of the treatment. This could provide direct clinical implications in 
actual practice. With reference to the results of this study, injury prevention should be 
considered as one of the benefits of ADHD medication in clinical practice.   
4.1 Strengths and limitations 
We undertook a rigorous systematic review and meta-analysis which included all 
relevant literature to date. Reviewer selection bias was minimised by using a predefined 
search strategy for selection and data extraction being conducted by two independent authors. 
Differences in study designs, exclusion criteria, control groups, duration of follow-up, 
covariates included and analysis model can affect the accuracy of pooled estimates. We 
observed moderate to high heterogeneity in the pooled estimates. This may represent the 
difference in the analysis for each study, in particular which covariates were included and 
what analysis model was used; therefore some of the results should be interpreted with 
caution. However all studies were essentially measuring similar outcomes and there is no 
indication of large clinical heterogeneity to invalidate our meta-analysis and narrative 
reviews. More importantly the forest plots of the two analyses are consistent and make 
biological sense; thus, we believe it is appropriate to numerically summarize the results of 
some but not all studies in this systematic literature review. As the number of studies included 
in the meta-analysis is limited, a funnel plot was not performed as it would not reliably 
identify publication bias. In addition, the studies identified for meta-analysis are relatively 
recent (2009-2017) with similar results; therefore we cannot exclude the possibility of 





The results from this meta-analysis support that pharmacological treatment could 
lower the risk of injuries by an average of 13%. The benefit of ADHD medications in injury 
reduction may be associated with age, with greater benefit in older adolescents and adults. 
While the traditional consideration of ADHD management has been on improving academic 
performance, trauma prevention is another important aspect of care and should be further 
considered in the broader clinical assessment and management of ADHD when medications 
are prescribed. 
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cIRR = incidence rate ratio, HR = hazard ratio, OR = odds ratio, RR = rate ratio 
dMethylphenidate and atomoxetine  
e International Classification of Diseases (ICD)-9 codes 800–995, excluding ICD-9 codes 905–909 (late effects of injuries, poisonings, toxic effects and other external causes) and specifically 
fractures (ICD9 800–829), intracranial injuries (ICD-9 850–854) and open wounds (ICD-9 870–897) 
fICD-9 codes 800-829 
gICD-9-CM codes 800–999, including fractures (ICD-9-CM 800–829), dislocations (ICD-9-CM 830–839), sprains and strains (ICD-9-CM 840–849), intracranial/ internal injuries (ICD-9-CM 
850–869), open wounds (ICD-9-CM 870–899), injury to blood vessels (ICD-9-CM 900–904), superficial injuries/contusions (ICD-9-CM 910–924), crushing injuries (ICD-9-CM 925–929), 
foreign body entering through an orifice (ICD-9-CM 930–939), burns (ICD-9-CM 940–949), injury to nerves and spinal cord (ICD-9-CM 950–957), poisoning (ICD-9-CM 960–989), and any 
others 
hAdderall, Concerta, Metadate, Methylin, Methylpheni, Pemoline, Ritalin, and Strattera 
iICD-9 codes 800-957 
jStimulant (methylphenidate N06BA04, amphetamine N06BA01, and dexamphetamine N06BA02) and nonstimulant (atomoxetine N06BA09) medications 
kICD-10 codes V01-V99 
lIndividual who received ADHD diagnosis or ADHD medication (amphetamine salt combination, atomoxetine hydrochloride, dexmethylphenidate hydrochloride, dextroamphetamine 
sulfate, lisdexamfetamine dimesylate, methamphetamine hydrochloride, methylphenidate, and methylphenidate hydrochloride) 
mICD-10-DCR codes S00-S99 or T08-T14, primary and secondary diagnoses 
nTreated defined as treated with dexamphetamine (N06BA02), methylphenidate (N06BA04), or atomoxetine (N06BA09) for ≥6 months within a year before age 10 
  
 
oPhysicians identified trauma-related admission identified by a code in CDARS 
pNew diagnoses defined as ≥1 inpatient diagnosis of ADHD (ICD-10-GM code F90.0 or F90.1); ≥2 outpatient diagnoses of ADHD; ≥1 outpatient diagnosis of ADHD and ≥1 outpatient 
diagnosis with the unspecific ICD-10-GM code F90.9; ≥1 outpatient diagnosis of ADHD and ≥1 prescription of methylphenidate or atomoxetine within 365 days 
qCoded as ADHD or hyperkinetic disorder 
rMethylphenidate, dexamphetamine 
sFracture of upper limb; Intracranial injuries excluding skull fracture; Traumatic complications/unspecified injury; Sprains and strains; Superficial injury (abrasions, blisters, stings, bites); 
Contusion (bruise) and intact skin; Fracture of lower limb; Open wound head/neck/trunk; Poisoning (medicinal agent); Open wound of upper limb; Fracture of skull; Crushing injury; 





Table 2. Quality assessment of included studies using the Newcastle-Ottawa Scale. 
Study Study design Selection Comparability Exposure/ outcome Total 
van den Ban et al. (2014) [13] C ****  *** 7 
Chang et al. (2014) [14] SCC **** ** *** 9 
Chen et al. (2017) [15] C ****  *** 7 
Chien et al. (2017) [16] C ****  *** 7 
Dalsgaard et al. (2015) [17] SCC **** ** *** 9 
Man et al. (2015) [6] SCCS **** ** *** 9 
Merrill et al. (2009) [18] C ***  *** 6 
Mikolajczyk et al. (2015) [4] SCCS **** ** *** 9 
Raman et al. (2013) [5] SCCS **** ** *** 9 
Chang et al. (2017) [19] SCC **** ** *** 9 
C = cohort, SCC = self-controlled cohort (only consider within-individual analysis), SCCS = self-controlled case series  
 
 
